Morimoto Ken, Koh Masae, Yamamoto Akira, Tamura Kazutomi, Yamamoto Kumio, Yamamoto Keishi, Suehiro Shigefumi
Dept. of Breast, Head and Neck Surgery, Ishikiriseiki Hospital.
Gan To Kagaku Ryoho. 2006 Jul;33(7):925-9.
Changes in level of estrogen receptor (ER) and progesterone receptor (PgR) and their affecting factors were studied with metastasis or recurrence of breast cancer. Since 1983, from 177 patients, 443 specimens were obtained and 244 simultaneous and 122 sequential pairs were compared. The consistency rate was 81% for both ER and PgR with simultaneous comparison,and 69% for ER and 71% for PgR with sequential comparison, mainly due to positive-to-negative change, and less than 10% of negative-to-positive change. Positive-to-negative change was prominent with intervening endocrine treatment, and it was significant (p=0.015) for ER by multiple regression analysis of age, interval of sampling and from prior surgery, intervening chemotherapy, endocrine therapy and human epidermal growth factor receptor 2 (HER 2). Based on recent data of ER and PgR, feasible treatment seems to be planned, because about 30% of them are different from that of primary lesion.
研究了雌激素受体(ER)和孕激素受体(PgR)水平的变化及其影响因素与乳腺癌转移或复发的关系。自1983年以来,从177例患者中获取了443份标本,并对244对同步标本和122对序贯标本进行了比较。同步比较时ER和PgR的一致性率均为81%,序贯比较时ER为69%,PgR为71%,主要是由于阳性转阴性变化,阴性转阳性变化不到10%。在进行内分泌干预治疗时,阳性转阴性变化较为突出,通过对年龄、采样间隔、上次手术时间、干预化疗、内分泌治疗及人表皮生长因子受体2(HER 2)进行多元回归分析,ER出现这种变化具有显著性(p=0.015)。基于ER和PgR的最新数据,似乎可以制定可行的治疗方案,因为其中约30%与原发病变不同。